Search results
Results from the WOW.Com Content Network
Endobronchial valves are medical devices that allow air to exit these sections but not to re-enter. The valves, in effect, cause damaged lung tissue to deflate, thereby reducing the excessive lung volume (hyperinflation) caused by emphysema. Two endobronchial valves have been approved by the FDA for BLVR: Zephyr and Spiration. [citation needed]
Improvement in quality of life has also been considered as success even if more than 1 pad/day was needed. The success rate was reported at 78% with a 3-year follow-up, [27] and over 72% with 5 to 7 years of follow-up. [28] In a recent systematic review, the success rate was reported to be 79% with follow-up period ranging from 5 months to 16 ...
Zephyr Surgical Implants (ZSI) is a Swiss-based medical device manufacturer that produces and distributes artificial urinary sphincters and penile implants worldwide. ZSI products are used in the management of moderate-to-severe urinary incontinence in men, erectile dysfunction, Peyronie's disease, penis enlargement, and female-to-male gender reassignment surgery.
Endobronchial valve. An endobronchial valve (EBV) is a small, one-way valve, which may be implanted in an airway feeding the lung or part of lung. The valve allows air to be breathed out of the section of lung supplied, and prevents air from being breathed in. This leaves the rest of the lung to expand more normally and avoid air-trapping.
St Jude Medical's Portico Transcatheter aortic valve received European CE mark approval in December 2013. The valve is repositionable before release to ensure accurate placement helping to improve patient outcomes. [12] Edwards' Sapien aortic valve is made from bovine pericardial tissue and is implanted via a catheter-based delivery system. It ...
The positive response rate was 3.4% lower for Jewish Americans and 4.9% lower for Israeli-Americans compared to other backgrounds such as those with Italian or Irish heritage, according to the report.
Nvidia stock jumped as much as 2.7% early Thursday as Wall Street analysts reiterated their Buy ratings on the stock despite concerns about rising competition and the possibility that artificial ...
Complications occur in 3% to 5% of cases with one to 3% chance of early death. The death rate is almost negligible in very experienced centres. 80% to 90% of cases survive 10 years, and 70% to 80% may live up to 20 years. [3] As of 2014, the Ross procedure comprises less than 1% of all aortic valve replacements in North America. [1]